v
Search
Advanced

Publications > Journals > Most Viewed Articles

Results per page:
v
Review Article Open Access
Songgen Jin, Yunpeng Luo, Songliu Yang, Shixing Wu, Changsong Wang
Published online September 28, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 496
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2026.00003S
Abstract
Human serum albumin (HSA) is a multifunctional carrier protein that helps maintain vascular barrier integrity and intravascular fluid homeostasis and has long been used in the management [...] Read more.

Human serum albumin (HSA) is a multifunctional carrier protein that helps maintain vascular barrier integrity and intravascular fluid homeostasis and has long been used in the management of critically ill patients, including those with acute brain injury. HSA is thought to exert neuroprotective effects through four complementary mechanisms: oncotic/volume expansion and hemodilution, antioxidant and anti-inflammatory effects, HSA-nitric oxide-mediated antithrombotic activity, and glycocalyx stabilization, although the precise pathways remain incompletely understood. Despite its biological rationale, the clinical efficacy of HSA in severe neurological disorders remains inconclusive, and few guidelines provide specific recommendations for its use in neurological care. This uncertainty stems primarily from the complex etiology and heterogeneous pathophysiology of neurological disorders, as well as inconsistent findings across existing studies. This narrative review aims to summarize the current evidence on HSA use in traumatic brain injury, acute ischemic stroke, and aneurysmal subarachnoid hemorrhage, identify existing knowledge gaps, and provide insights for future research and clinical practice. We screened records from PubMed, Embase, the Cochrane Library, CNKI, and Yiigle, as well as ClinicalTrials.gov, ChiCTR, and ChinaDrugTrials. A total of 29 human and animal studies were included. Collectively, available evidence supports a biological rationale for HSA therapy in neurocritical care, yet its clinical benefit remains incompletely established and substantial challenges persist. Prospective randomized controlled trials are warranted to clarify the efficacy and safety of HSA and determine whether preliminary encouraging findings can inform standardized guidelines and expert consensus recommendations, particularly regarding optimal concentration, timing, and patient selection.

Full article
Corrigendum Open Access
Original Article Open Access
Gen Li, Ming Cheng, Jian He, Dengfeng Huang, Yingying Zhou, Yaohui Gao, Yuming Sun, Zhizhen Li
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 427
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00174
Abstract
Intraoperative hypotension (IOH) is a common and serious complication associated with increased perioperative morbidity and mortality. Although obstructive jaundice is often accompanied [...] Read more.

Intraoperative hypotension (IOH) is a common and serious complication associated with increased perioperative morbidity and mortality. Although obstructive jaundice is often accompanied by hemodynamic instability, its mechanistic contribution to IOH remains unclear. In this study, we aimed to determine whether jaundice affects IOH and elucidate the underlying mechanism.

Clinical data from 139 patients who underwent pancreatoduodenectomy were retrospectively analyzed for predictors of IOH. Vascular tissues from jaundiced and non-jaundiced patients were subjected to single-cell RNA sequencing for cell-specific molecular exploration. Key findings were validated by immunohistochemistry in a stratified random sample from the study cohort. In a rat bile duct ligation model, aortic endothelin-1 (EDN1) expression and vascular function were assessed by Western blotting and ex vivo vascular reactivity assays. The mechanism was investigated in primary mouse aortic endothelial cells under TNF-α stimulation with or without NF-κB pathway inhibition.

Multivariable logistic regression identified jaundice as an independent predictor of IOH (odds ratio, 2.328; 95% confidence interval, 1.027–5.276; P = 0.043). Jaundiced tissues exhibited vascular cell remodeling, characterized by increased proportions of endothelial cells and macrophages and decreased proportions of fibroblasts and smooth muscle cells. EDN1 expression was significantly downregulated in jaundiced patients, and total bilirubin levels were negatively correlated with EDN1 protein expression (P < 0.001). Single-cell RNA sequencing of immune cells suggested suppression of the NF-κB pathway in jaundiced patients. In the bile duct ligation model, EDN1 expression in aortic tissue showed a time-dependent decrease. In TNF-α-stimulated primary mouse aortic endothelial cells, bilirubin or NF-κB inhibition with BAY 11-7082 suppressed EDN1 expression.

Biliary obstruction causing jaundice may contribute to IOH through suppression of NF-κB signaling and reduced endothelial EDN1 expression. These findings support further investigation of the NF-κB/EDN1 signaling axis as a potential therapeutic target for jaundice-associated IOH.

Full article
Original Article Open Access
Lucy Ogoke, Sangwook Michael Woo, Nicole Herbers, Michael Chen, Hua Yang, Amy Bazzarelli, Wei Xiong
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 427
Journal of Clinical and Translational Pathology. doi:10.14218/JCTP.2026.00043
Abstract
Fine-wire-guided localization (FWGL) has traditionally been used for nonpalpable breast lesions although it can complicate specimen handling. Magnetic Occult Lesion Localization [...] Read more.

Fine-wire-guided localization (FWGL) has traditionally been used for nonpalpable breast lesions although it can complicate specimen handling. Magnetic Occult Lesion Localization and Imaging (MOLLI) is a wire-free alternative for which comparative pathologic data remain limited. This exploratory study examined margin status, morphometry, and specimen integrity.

We retrospectively analyzed 109 consecutive lumpectomy specimens (83 MOLLI, 26 FWGL) at a single academic center between March 2022 and April 2023, comprising 108 primary excisions and one re-excision. The localization method was not randomly assigned and appears to have depended on surgeon preference. Secondary invasive-carcinoma analyses used Firth penalized logistic regression to adjust for potential confounding.

After exclusion of 33 benign lesions, 76 carcinomas remained (62 invasive carcinomas and 14 cases of pure ductal carcinoma in situ), 75 with evaluable primary-excision margins. For the primary outcome, positive margins occurred in 13.8% (8/58) of MOLLI versus 17.6% (3/17) of FWGL cases (P = 0.70). In the secondary invasive-carcinoma analysis, positive margins occurred in 10.9% (5/46) versus 18.8% (3/16) (P = 0.41). Median specimen weight and volume did not differ significantly; specimen integrity was preserved in 98.8% (82/83) of MOLLI and 100% (26/26) of FWGL specimens.

In this exploratory study, MOLLI shows no detectable differences in margin status, morphometry, or specimen integrity relative to fine-wire localization. Unlike published data on a related magnetic-seed device, we observe no reduction in resected tissue volume, indicating that findings for one device should not be assumed to apply to another. The study is underpowered to detect small differences. These preliminary findings therefore require confirmation in larger studies.

Full article
Review Article Open Access
Elena Bonora, Elisa Boschetti, Visha Parmar, Saranya Arumugam, Roberto De Giorgio, Shanthi Srinivasan, John W. Wiley
Published online November 16, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 408
Journal of Translational Gastroenterology. doi:10.14218/JTG.2026.00033
Abstract
Chronic constipation is common, heterogeneous, and often incompletely controlled. This review evaluates cellular and molecular evidence and proposes a roadmap for testing candidate [...] Read more.

Chronic constipation is common, heterogeneous, and often incompletely controlled. This review evaluates cellular and molecular evidence and proposes a roadmap for testing candidate endotypes. We distinguish established physiology and clinical efficacy from human associations, causal effects in experimental systems, and unvalidated hypotheses. Relevant mechanisms involve enteric neurons and glia, pacemaker and smooth muscle networks, epithelial transport, enteroendocrine signaling, microbial metabolites, and pelvic floor coordination. Five candidate endotypes address neuronal composition, pacemaker dysfunction, methanogen enrichment, neuroimmune activation, and cortical–pelvic coordination; pharmacogenomics provides a cross-cutting strategy. Each proposal links measurable features to appropriate sampling and prospective tests that can exclude clinically meaningful effects. Cellular sequencing, spatial RNA and protein profiling, and multimodal integration can identify candidate signatures. Organoid and animal perturbations test mechanisms within models; clinical usefulness additionally requires reproducible assays, independent validation, randomized treatment-interaction tests, and patient benefit. Rome V criteria provide a cohort framework, with the criteria version recorded explicitly. A staged program should begin with clinical phenotyping and biospecimen banking, add mucosal studies, and develop multicenter full-thickness tissue collections for neuromuscular questions. This approach addresses cost, selection bias, and tissue access while distinguishing mechanistic discovery from useful treatment guidance.

Full article
Review Article Open Access
Gerd Klinkmann, Claudio Ronco, on behalf of the Studies Utilizing Blood Purification in Limiting the Overdose in Treatments (SUBPLOT) Investigators
Published online September 30, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 367
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2026.00004S
Abstract
Extracorporeal treatment (ECTR) is used in selected severe poisonings to enhance toxin elimination and, in some cases, provide temporary organ support. Modalities include intermittent [...] Read more.

Extracorporeal treatment (ECTR) is used in selected severe poisonings to enhance toxin elimination and, in some cases, provide temporary organ support. Modalities include intermittent hemodialysis, continuous renal replacement therapy, and sorbent-based hemoperfusion or hemoadsorption, each with distinct mechanisms and toxicokinetic implications. This narrative review summarizes modality-specific and toxin-specific evidence, operational treatment characteristics, patient-centered and toxicokinetic outcomes, safety considerations, and scenarios in which ECTR should be withheld, and proposes a practical five-step bedside algorithm. Sources were identified through targeted searches of PubMed/MEDLINE and Google Scholar, supplemented by Extracorporeal Treatments in Poisoning (EXTRIP) consensus documents, reference-list screening, and author expertise. The evidence base varies substantially across toxins. For several pharmaceutical poisonings, EXTRIP provides the most actionable guidance on indications, preferred modality, and stopping criteria, while recommending against ECTR for digoxin and methotrexate. Outside these consensus-guided settings, the largest experience with sorbent therapies concerns paraquat and organophosphorus/carbamate poisoning, although the literature is regionally concentrated and predominantly observational. In paraquat poisoning, hemoadsorption-containing strategies have been associated with improved survival in observational cohorts, while pharmacokinetic studies support early and repeated treatment in selected patients because of ongoing toxin removal and post-treatment rebound. In organophosphorus/carbamate poisoning, comparative studies suggest possible benefit in severe presentations, but certainty remains low. In diquat poisoning, recent reports emphasize concentration-directed extracorporeal strategies. Evidence for other toxins is largely limited to feasibility, toxin removal, and case-based experience. ECTR should therefore be regarded as a toxin-specific therapeutic toolbox rather than a uniform intervention. Where available, EXTRIP recommendations should guide practice. Otherwise, modality selection should integrate toxicokinetic plausibility, clinical severity, feasibility, and safety. Prospective studies using standardized prescriptions and clinically meaningful endpoints are needed.

Full article
Review Article Open Access
Di Meng, Zhenyao Jiang, Yingcheng Yao, Mingming Ye, Sitian Zhao, Mingyang Jin, Jie Li, Junping Shi
Published online November 16, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 362
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00242
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a [...] Read more.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a major global health challenge. Current management relies primarily on comprehensive lifestyle interventions, including dietary modification, regular physical activity, weight loss, management of metabolic risk factors, and emerging pharmacotherapies. The gluten-free diet (GFD) was originally developed for the treatment of celiac disease and has attracted attention in recent years for its potential metabolic benefits. Existing studies suggest that gluten- or wheat-targeted dietary interventions may affect MASLD-related pathways, including the gut microbiota, inflammation, insulin sensitivity, and liver fat accumulation. In patients with concurrent celiac disease and MASLD, a GFD is indicated for celiac disease, but its hepatic and metabolic effects are variable. However, clinical and mechanistic evidence for its potential effects in patients with non-celiac MASLD is limited and heterogeneous, relying largely on indirect evidence from animal models; furthermore, long-term, unsupervised adherence to a GFD may adversely affect metabolic health. This narrative review critically evaluates the therapeutic boundaries of gluten-targeted interventions, compares the gluten-free diet with established dietary patterns, and outlines challenges related to nutritional adequacy, cost, and adherence. Future research should focus on high-quality randomized controlled trials to identify the specific benefits and risks of gluten removal in patients with non-celiac MASLD and to inform more precise dietary guidance.

Full article
Review Article Open Access
Tian Li, Yong Yuan, Xiaofeng Li, Xiaoxia Hao
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 350
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00343
Abstract
Liver fibrosis is a dynamic and partially reversible pathological process driven by chronic liver injury, yet effective antifibrotic therapies remain limited. Astragaloside IV (AS-IV), [...] Read more.

Liver fibrosis is a dynamic and partially reversible pathological process driven by chronic liver injury, yet effective antifibrotic therapies remain limited. Astragaloside IV (AS-IV), a major bioactive constituent isolated from Astragalus mongholicus Bunge, exerts a broad range of pharmacological effects, including anti-inflammatory, antioxidant, and antifibrotic effects. This review synthesizes current evidence on the pharmacological characteristics, mechanistic basis, preclinical efficacy, and translational challenges of AS-IV in liver fibrosis. Available evidence indicates that AS-IV exerts its antifibrotic effects primarily by suppressing hepatic stellate cell activation, with modulation of transforming growth factor-β/Smad signaling representing the most consistently supported mechanism. Beyond this principal pathway, AS-IV may attenuate profibrotic amplification loops by enhancing antioxidant responses and suppressing inflammatory signaling, while also reducing upstream profibrotic stimuli through hepatoprotective effects. However, its clinical translation remains limited by poor oral bioavailability, inadequately defined pharmacokinetic-pharmacodynamic relationships, and a lack of high-quality clinical evidence. Overall, AS-IV represents a promising preclinical antifibrotic candidate, although clinical efficacy and pharmacological optimization remain to be established.

Full article
Letter to the Editor Open Access
Jiale Tang, Lingyu Ren, Chao Sun, You Deng
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 296
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00704
Review Article Open Access
He Ma, Jia-Rui Zheng, Xin-Kun Liu, Lin-Xiang Huang, Yan-Di Xie, Bo Feng
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 290
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00549
Abstract
Achieving a functional cure for chronic hepatitis B remains challenging, primarily due to the inability to reconstitute effective host immune responses against the virus. The unexpected [...] Read more.

Achieving a functional cure for chronic hepatitis B remains challenging, primarily due to the inability to reconstitute effective host immune responses against the virus. The unexpected functional cure of chronic hepatitis B following allogeneic hematopoietic stem cell transplantation provides a unique proof-of-principle model for immune-mediated HBsAg clearance. This review aims to elucidate that the core mechanism underlying hematopoietic stem cell transplantation-mediated HBsAg clearance lies in “adoptive immune transfer”, and to explore design principles and future directions for modern cell-based immunotherapies based on this mechanism. We reviewed available case reports and meta-analytic evidence, acknowledging their limitations, and dissected the immunological mechanisms by which donor-derived hepatitis B virus-specific T and B cells may jointly reconstitute adaptive immunity and break host immune tolerance. We then comparatively evaluated the technical characteristics and limitations of chimeric antigen receptor T cell therapy and T-cell receptor-engineered T-cell therapy. Current engineered T-cell therapies, while translating the core principle of adoptive transfer, exhibit fundamental limitations including monoclonal specificity, inability to remodel the host microenvironment, and absence of durable humoral reconstitution. A broader functional-cure strategy may require adopting the paradigm of synergy and systemic immune reshaping exemplified by hematopoietic stem cell transplantation. Future strategies should develop temporally optimized, multilayered combination therapies, offering a possible pathway for next-generation therapeutics capable of systemically rebuilding antiviral immunity.

Full article
PrevPage 35 of 36 12…3233343536Next
Back to Top